Gynecologic Cancer

The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 neutropenia and septic shock.

After a brain cancer diagnosis, Dr. Bobby Mukkamala says becoming a patient highlighted care barriers, emotions and the need for access and support.

Newly diagnosed with cancer? This oncofertility guide covers egg freezing, sperm banking, and critical questions for your oncologist.

FDA granted breakthrough therapy designation to sofetabart mipitecan for adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

Learn about stage 2 vaginal cancer, including symptoms, diagnosis, treatment options, side effects and questions to discuss with your care team.

A young cancer survivor who underwent external beam radiation therapy and brachytherapy at 14 years old discusses her rare diagnosis, side effects and the nonlink to her Turner syndrome.

Adding Tecentriq to chemo resulted in survival outcomes comparable to placebo plus chemo in patients with advanced or recurrent endometrial cancer.

Addressing spirituality and religion can potentially help patients with gynecologic cancers, researchers have found.

Women with a history of cervical cancer are nearly twice as likely to develop anal cancer as members of the general population, according to researchers.

Early-stage gynecologic cancer is confined to its original site and often treatable; diagnosis, surgery, and new therapies improve outcomes.

Rina-S earned breakthrough therapy designation for patients with advanced endometrial cancer whose disease has worsened after platinum-based chemotherapy.

I wrote a poem about life with endometrial cancer, rejecting pity and embracing strength, connection and the dignity of being truly seen.

Thirteen years after cervical cancer, I’ve found strength in healing, grief in silence, and hope in sharing the quiet truths of survivorship.

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.

Dr. Ritu Salani discussed Cervical Cancer Awareness Month, highlighting what patients with this disease should be aware of as well as prevention tactics.

From the death of a TikTok influencer to an update from a “Boy Meets World” star, here is this week’s news.

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve outcomes versus chemotherapy.

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Susan K. Bohnenkamp, an oncology clinical nurse specialist, is recognized for her compassionate and expert care, going above and beyond to support her patients through their cancer journey.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.

Induction chemotherapy shows significant improvements for survival in patients with locally advanced cervical cancer.

Patients with cervical cancer demonstrated better sexual health and quality of life after undergoing simple hysterectomies versus radical hysterectomies.

Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.